

IN THIS ISSUE

- 16 Arrhythmias & Electrophysiology**
Implant patients make a psychological adjustment to living with an ICD.
- 21 Epidemiology & Prevention**
For women only: Aspirin reduces the risk of a first stroke.
- 22 Acute Coronary Syndromes**
Lowering treatment targets in ACS patients reduces adverse event rates.
- 23 Cerebrovascular Disease**
Inadvertent overdosing of ischemic stroke patients with TPA may undermine the drug's effect.
- 24 CAD & Atherosclerosis**
A large proportion of hypertensive diabetics also have silent CAD.
Guest Editorial: To prevent stroke, treat the disease, not the lesion, says Dr. Anthony S. Wierzbicki.
- 26 Heart Failure**
Nesiritide didn't affect renal function in stable heart failure patients in a phase II study.
- 28 Interventional Cardiology**
Cardiologists question the latest PCI guideline revision.
- 31 Practice Trends**
Policy & Practice
Physician groups oppose plans to implement voluntary quality reporting program for Medicare, 33
- 34 Letters**
- 35 On the Beat**

Reader Services

Classifieds, 31

Index of Advertisers, 32

EDITORIAL
ADVISORY BOARD

- SIDNEY GOLDSTEIN, M.D.**, Michigan
Medical Editor
- JONATHAN ABRAMS, M.D.**, New Mexico
Associate Medical Editor
- ERIC R. BATES, M.D.**, Michigan
- GEORGE BELLER, M.D.**, Virginia
- STEVEN F. BOLLING, M.D.**, Michigan
- ROBERT M. CALIFF, M.D.**, North Carolina
- PRAKASH C. DEEDWANIA, M.D.**, California
- KIM A. EAGLE, M.D.**, MICHIGAN
- JAMES J. FERGUSON, III, M.D.**, Texas
- JOHN FLACK, M.D.**, Michigan
- THOMAS D. GILES, M.D.**, Louisiana
- ANTONIO M. GOTTO, Jr., M.D.**, New York
- DAVID L. HAYES, M.D.**, Minnesota
- DAVID R. HOLMES, Jr., M.D.**, Minnesota
- BARRY M. MASSIE, M.D.**, California
- CHRISTOPHER M. O'CONNOR, M.D.**,
North Carolina
- NATESA G. PANDIAN, M.D.**, Massachusetts
- ILEANA L. PIÑA, M.D.**, Ohio
- OTELIO RANDALL, M.D.**, Washington, D.C.
- THOMAS J. RYAN, M.D.**, Massachusetts
- HANI N. SABBAH, Ph.D.**, Michigan
- LESLIE ANNE SAXON, M.D.**, California
- DAVID H. SPODICK, M.D.**, Massachusetts
- NEIL J. STONE, M.D.**, Illinois
- PAUL D. THOMPSON, M.D.**, Connecticut
- ROBERTA WILLIAMS, M.D.**, California

HEART OF THE MATTER
A Lull in the War on Heart Disease

By all appearances, we have reached a plateau in our attack on heart disease, and the recent meeting of the American Heart Association in Dallas provided ample evidence of this.

Numerous presentations and clinical trials were reported at the meeting, and some are included in this issue of CARDIOLOGY NEWS. But the findings reported have not moved us very far forward. Clinical trials spanning a variety of targets failed to show any significant benefits. Much of what was reported compared one drug or device with another, with an eye to safety rather than showing any improvement in mortality or morbidity.

In many cases, investigators examined new stents and antithrombotic drugs, but provided no reason to deviate from current practice. Some studies suggested that one stent might be better than another, but were often conducted in differing patient populations, which modulated most of the observed benefits and negated the differences.

In the device area, a variety of new techniques directed at improving the marginal benefits of ablation therapy

for atrial fibrillation were reported. Several studies focused on trying to identify those patients who benefit the most from biventricular pacing.

More surprisingly, the results of the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) indicated that heart failure mortality increased significantly after a single discharge of the defibrillator. These observations suggested that the MADIT II patients were trading sudden death for progressive heart failure. There was no ready explanation for these observations, which generated

considerable discussion among attendees about the trade-off.

The results of two clinical trials with levosimendan, a calcium-sensitizing drug for heart failure that is available in Europe but not approved in the United States, were also reported. Although patients seemed to experience improvement in symptoms acutely, morbidity and mortality were not significantly improved. It seems that current heart failure therapy with intravenous inotropic drugs supports patients through the acute episode, only to expose them to repeat and progressive failure. The

cost of this support is further myocardial damage. It is becoming clear that there is a need for drugs that will improve cardiac function without causing cell damage in the setting of acute heart failure, a syndrome that is drawing increasing interest from investigators.

In the area of lipid therapy, fenofibrate was studied in patients with type 2 diabetes. There was a significant decrease in nonfatal MIs, but also a non-significant increase in total mortality.

With some certainty, our major therapeutic tools have stood the test of examination during the last year, but they have not provided a window to any new therapies. It seems that we have lowered cardiac mortality to a level that might make it difficult to demonstrate drug benefit.

Perhaps these observations will become more pertinent to the future of cardiology as costs and reimbursements begin to play an even greater role in our decision making. It is possible that we may be pricing ourselves out of the market as the numbers in our uninsured population burgeon. ■

DR. GOLDSTEIN, *medical editor of CARDIOLOGY NEWS, is professor of medicine at Wayne State University and division head, emeritus, of cardiovascular medicine at Henry Ford Hospital, Detroit.*

Cardiology News

President, IMNG Alan J. Imhoff

Executive Editor Mary Jo M. Dales

Publication Editor Catherine Hackett

Publication Associate Editor Renée Matthews

Senior Editors Kathryn DeMott, Denise Fulton, Gina L. Henderson, Sally Koch Kubetin, Teresa Lassman, Mark S. Lesney, Catherine Cooper Nellist, Calvin Pierce, Terry Rudd, Kathy Scarbeck, Elizabeth Wood

Associate Editors Christina Chase, Jay C. Cherniak, Richard Franki, Deeanna Franklin, Randall Frey, Joyce Frieden, Gwendolyn Hall, Jennifer Lubell, Amy Pfeiffer, Robin L. Turner

Bureaus Betsy Bates (Los Angeles), Sherry Boschert (San Francisco), Doug Brunk (San Diego), Bruce K. Dixon (Chicago), Robert Finn (San Francisco), Bruce Jancin (Denver), Kate Johnson (Montreal), Timothy F. Kirn (Sacramento), Jane Salodof MacNeil (Southwest), Diana Mahoney (New England), Damian McNamara (Miami), Michele G. Sullivan (Mid-Atlantic), Nancy Walsh (New York), Patrice Wendling (Chicago), Sharon Worcester (Southeast), Mitchel L. Zoler (Philadelphia)

Senior Writers Jeff Evans, Kevin Foley, Elizabeth Mechatie, Mary Ellen Schneider, Heidi Splete, Miriam E. Tucker, Kerri Wachter

Contributing Writers Alicia Ault, Nellie Bristol, Christine Kilgore, Mary Ann Moon

Copy Chief Felicia R. Black

Assistant Copy Chief Carol Nicotera-Ward

Copy Editors John R. Bell, Therese Borden, Virginia Ingram-Wells, Rachel Keith, Jane Locastro, Jeannie Massie, Leanne Sullivan

Editorial Offices 12230 Wilkins Ave., Rockville, MD 20852, 800-445-6975, cardiologynews@elsevier.com

Executive Director, Operations Jim Chicca

Director, Production/Manufacturing

Yvonne Evans

Production Manager Judi Sheffer

Production Specialists Anthony Draper, Thomas Humphrey, Rebecca Slebodnik, Mary D. Templin

Information Technology Manager Doug Sullivan

Senior Systems Administrator Lee J. Unger

Systems Administrator Drew Mintz

Operations Assistant Melissa Kasimatis

Art Director Louise A. Koenig

Assistant Design Supervisor

Elizabeth B. Lobdell

Design Staff Sarah L. Gallant, Forhad S.

Hossain, Julie Keller, Angie Ries

Photo Editors Vivian E. Lee, Sheryllynn M. Mattes,

James E. Reinaker

Project Manager Susan D. Hite

Assignments Coordinator Megan Evans

Departmental Coordinator Vicki Long

Editorial Coordinator Daniela Silva

H.R. Manager Philip Cooksey

Regional Manager of Facilities Chris Horne

Receptionist YoLanda L. Mitchell

Address Changes Fax change of address (with old mailing label) to 301-816-8736 or e-mail change to subs@elsevier.com

CARDIOLOGY NEWS is an independent newspaper that provides the practicing specialist with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician's practice.

The ideas and opinions expressed in CARDIOLOGY NEWS do not necessarily reflect those of the Publisher. Elsevier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

V.P., Med. Ed./Bus. Development

Sylvia H. Reitman

Program Managers, Med. Ed. Sara M. Hagan,

Malika Wicks

Senior Director, Marketing/Research

Janice Theobald

Marketing Associate Jennifer Savo

Sales Director Mark E. Altier

Executive Director, Business Operations

Bari Edwards

Bus. Manager Brian O'Connor

Adv. Services Manager Joan Friedman

Credit Supervisor Patricia H. Ramsey

Manager, Administration/Conventions

Lynne Kalish

Sales Assistant Kathy Craine

Receptionist Linda Wilson

National Account Managers Sue Fagan,

973-290-8226, s.fagan@elsevier.com;

Barbara Napoli, 973-290-8224, b.napoli@

elsevier.com; Christy Tetterton, 973-290-

8231, c.tetterton@elsevier.com

Advertising Offices 60 Columbia Rd., Bldg. B,

Morristown, NJ 07960, 973-290-8200,

fax 973-290-8250

Classified Sales Manager Robin Cryan, 212-

633-3160, r.cryan@elsevier.com

Classified Advertising Offices 360 Park Ave.

South, 9th Floor, New York, NY 10010,

800-379-8785, fax 212-633-3820

Reprints Call 301-816-8726

POSTMASTER Send changes of address (with old mailing label) to Circulation, CARDIOLOGY NEWS, 12230 Wilkins Ave., Rockville, MD 20852.

CARDIOLOGY NEWS (ISSN 1544-8800) is published monthly by Elsevier Inc., 60 Columbia Rd., Building B, Morristown, NJ 07960, 973-290-8200, fax 973-290-8250. ©Copyright 2005, by Elsevier Inc.

INTERNATIONAL
MEDICAL NEWS
GROUPBPA
BUSINESS PUBLISHERS
ASSOCIATION